In last trading session, NovaBay Pharmaceuticals Inc. (AMEX:NBY) saw 1.51 million shares changing hands with its beta currently measuring 2.82. Company’s recent per share price level of $0.12 trading at $0.0 or 0.49% at ring of the bell on the day assigns it a market valuation of $6.92M. That closing price of NBY’s stock is at a discount of -541.67% from its 52-week high price of $0.77 and from its 52-week low price of $0.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.64 million shares which gives us an average trading volume of 745.91K if we extend that period to 3-months.
NovaBay Pharmaceuticals Inc. (AMEX:NBY) trade information
Upright in the green during last session for gaining 0.49%, in the last five days NBY remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $0.12 price level, adding 28.23% to its value on the day. NovaBay Pharmaceuticals Inc.’s shares saw a change of -67.42% in year-to-date performance and have moved -21.40% in past 5-day. NovaBay Pharmaceuticals Inc. (AMEX:NBY) showed a performance of -50.64% in past 30-days. Number of shares sold short was 1.24 million shares which calculate 2.62 days to cover the short interests.
NovaBay Pharmaceuticals Inc. (NBY) estimates and forecasts
Statistics highlight that NovaBay Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -59.60% of value to its shares in past 6 months, showing an annual growth rate of 40.00% while that of industry is 11.70. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 25.00% in the current quarter and calculating 60.00% increase in the next quarter. This year revenue growth is estimated to rise 102.40% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $3.51 million for the same. And 2 analysts are in estimates of company making revenue of $4.75 million in the next quarter that will end on Sep 2022. Company posted $2.13 million and $2.43 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 64.60% while estimating it to be 95.50% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 36.00% during past 5 years.
NovaBay Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between March 23 and March 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
NovaBay Pharmaceuticals Inc. (AMEX:NBY)’s Major holders
Insiders are in possession of 20.17% of company’s total shares while institution are holding 3.00 percent of that, with stock having share float percentage of 3.76%. Investors also watch the number of corporate investors in a company very closely, which is 3.00% institutions for NovaBay Pharmaceuticals Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at NBY for having 0.59 million shares of worth $0.18 million. And as of Mar 30, 2022, it was holding 1.12% of the company’s outstanding shares.
The second largest institutional holder is Renaissance Technologies, LLC, which was holding about 0.2 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 0.38% of outstanding shares, having a total worth of $59622.0.
On the other hand, Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 30, 2022, the former fund manager was holding 0.37 million shares of worth $0.11 million or 0.71% of the total outstanding shares. The later fund manager was in possession of 0.22 million shares on Mar 30, 2022, making its stake of worth around $64607.0 in the company or a holder of 0.41% of company’s stock.